Investigation of sarbecovirus exposure patterns and development of pan-sars-COV-2 neutralizing antibody responses in high-risk cohorts in myanmar

Ended Project Grant Awarded Last action

Award ID
R21AI175905
Recipient
Awarding agency
Obligated
$1,044,370

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Originally
Place of performance
Davis, CA, USA

Award details come from USAspending.gov.

Description

Abstract
Emerging severe acute respiratory syndrome coronavirus 2 (sars-COV-2) variants of concern pose a global challenge to the effectiveness of existing and future vaccines. This project will address questions surrounding the immunological response to different sarbecovirus exposure patterns with implications for vaccine development by conducting longitudinal repeated surveillance of unique human populations, previously determined to be highly exposed to a diversity of sars-COV-2-related coronaviruses in myanmar. There is a timely opportunity to follow these communities, particularly immediately following sars-COV-2 infection and/or vaccination to understand which previous sarbecovirus exposure patterns expand the likelihood of development of pan-sarbecovirus neutralizing antibodies. We will evaluate the impact of diverse patterns of natural and vaccination-based sarbecovirus exposure on development of pan- sarbecovirus neutralizing antibodies by following three specific human cohorts: (1) elephant loggers engaged in bushmeat hunting (including bats and pangolins) during the process of active deforestation of myanmar's remaining teak forests, (2) BAT guano harvesting communities surrounding hpaan cave systems in kayin state and (3) a previously uninvestigated population engaged in religious activities within the karst cave systems in the northern dawna range. Waxing and waning of specific antibody responses will be followed over time through use of pre-pandemic archived specimens from these populations and repeated prospective sampling. We will utilize a novel luminex bead-based multi-plex sarbecovirus assay, capable of simultaneously detecting neutralizing antibodies against 21 different HACE2-binding sarbecoviruses. Exposure patterns to specific sarbecoviruses will be identified and viral characteristics evaluated for their contribution to the likelihood of developing pan-sarbecovirus antibody responses, including viral genetic and functional phenotypic similarity and host plasticity (breadth of host species a virus is known to infect). Patterns of prior natural sarbecovirus exposure coupled with natural sars-COV-2 infection and / or vaccination will then be evaluated for contributions to broadly reactive antibody responses. Data generated through this project will inform on potential cross sarbecovirus clade vaccination strategies that could protect against both known and future emerging sars-COV-2 variants. We will also conduct an in-depth investigation of behavioral risk factors contributing to zoonotic sarbecovirus spillover that will aid in mitigation strategies in this critically important ecological region for coronavirus emergence.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Amendment $0
Amendment $214,874
Amendment $214,874
Amendment $0
Amendment $0
Amendment $204,874
Amendment $204,874
Original award $204,874

Subawards

Subrecipient Amount Awarded
National University Hospital (Singapore) PTE LTD Duke NUS Statement of work Duke�NUS will be responsible for conducting relevant assays for sarbecoviruses to be performed on specimens collected from… $53,268

Quick answers

Who received award R21AI175905?

R21AI175905 was awarded to University Of California, Davis by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 6, 2023.

How much is award R21AI175905 worth?

$1,044,370 has been obligated on R21AI175905.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award